| 货号 | AF229-SP |
| 别名 | CD30 antigen; CD30; CD30KI-1; CD30L receptor; cytokine receptor CD30; D1S166EKi-1; Ki-1 antigen; Lymphocyte activation antigen CD30; TNFRSF8; tumor necrosis factor receptor superfamily member 8; tumor necrosis factor receptor superfamily, member 8 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Immunocytochemistry(5-15 µg/mL) |
| 目标/特异性 | Detects human CD30 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross‑reactivity with recombinant mouse CD30 is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Agonist Activity: Measured by its ability to stimulate human IL-6 secretion by HDLM-2 human Hodgkin’s lymphoma cells. Gruss H.J. et al. (1996) Blood 87(6):2443. The ED50 for this effect is typically 0.2 - 0.6 μg/mL. Immunocytochemistry: 5-15 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 943 (Human); 21941 (Mouse); 25069 (Rat) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | S. frugiperda insect ovarian cell line Sf 21-derived recombinant human CD30 Phe19-Lys379 Accession # P28908 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Measured by its ability to stimulate human IL-6 secretion by HDLM-2 human Hodgkin’s lymphoma cells. Gruss H.J. et al. (1996) Blood 87(6):2443. The ED50 for this effect is typically 0.2 - 0.6 μg/mL. |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4 - 6). However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85-90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
CD30/TNFRSF8 in Jurkat Human Cell Line. CD30/TNFRSF8 was detected in immersion fixed Jurkat human acute T cell leukemia cell line using Goat Anti-Human CD30/TNFRSF8 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF229) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cell membrane and cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells. |
